News & Blog

November 23, 2021 | Blog Post
Partnerships are Key to Driving Innovation and Value in Drug Development: A View from the Top
November 16, 2021 | In The News
Endpoints News: Out to prove the next big I/O target, Immunitas’ chief dealmaker steps up to CEO role
November 16, 2021 | Press Release
Immunitas Therapeutics Names Amanda Wagner as CEO
November 09, 2021 | Blog Post
Artificial Intelligence and Drug Discovery: Cutting Edge AI to Address Pediatric Diseases
October 20, 2021 | Blog Post
Immunotherapy and Cancer: Cutting Edge Science to Address a Devastating Disease
September 08, 2021 | Press Release
Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer
September 07, 2021 | Blog Post
2021 Year to Date Update
August 19, 2021 | In The News
FinSMEs: Immunitas Therapeutics Closes $58M in Series B Financing
August 18, 2021 | In The News
Endpoints: Touting CD161 as a test case for single-cell tech, Longwood-backed Immunitas bags $58M for next-gen I/O work
August 18, 2021 | Press Release
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases